Respiratory

Following the science to improve patient outcomes

What will make the biggest difference?

Recent developments in the understanding of respiratory disease pathways mean that we are entering an era of unprecedented potential to deliver scientific breakthroughs and transform the lives of people with asthma and COPD. Our 40-year heritage in respiratory science is just the beginning of our story. Hear more from the people at AstraZeneca behind our commitment to respiratory disease.




Our pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

Phase 3/Reg.* refers to assets that are in Phase 3 or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.


Respiratory (as at 10 November 2016)

Phase 1

Phase 1

  • AZD1419 asthma
  • AZD5634 cystic fibrosis
  • AZD7986 COPD
  • AZD8871 COPD
  • AZD9567 rheumatoid arthritis
  • MEDI9314 atopic dermatitis

Phase 2

Phase 2

  • AZD7594 asthma/COPD
  • AZD9412 asthma/COPD
  • PT010 asthma
  • abediterol asthma/COPD
  • tezepelumab asthma/atopic dermatitis

Phase 3

Phase 3

  • Bevespi Aerosphere (PT003) GFF PINNACLE COPD
  • PT010 COPD
  • benralizumab CALIMA SIROCCO ZONDA BISE BORA GREGALE severe asthma
  • benralizumab TERRANOVA GALATHEA COPD
  • tralokinumab STRATOS 1,2 TROPOS MESOS severe asthma

LCM Projects

LCM Projects

  • Duaklir Genuair COPD
  • Symbicort breath actuated Inhaler asthma/COPD
  • Symbicort SYGMA as-needed use in mild asthma


Our medicines

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.

  • Accolate, Accoleit, Vanticon zafirlukast
  • Bricanyl Respules terbutaline
  • Bricanyl Turbuhaler terbutaline in a dry powder inhaler
  • Daliresp/Daxas roflumilast
  • Duaklir Genuair aclidinium/formoterol
  • Eklira Genuair/Tudorza/Bretaris aclidinium, a LAMA
  • Oxis Turbuhaler Oxis Turbuhaler
  • Pulmicort Turbuhaler budesonide
  • Pulmicort Respules budesonide inhalation suspension
  • Rhinocort budesonide
  • Symbicort pMDI budesonide/formoterol
  • Symbicort Turbuhaler budesonide/formoterol


New approaches in the treatment of asthma

Targeting the immune system to try and restore the balance in asthma patients

Read the full story


Commitment to science

Our commitment to science is reflected in our track record of publications. Here are a few recent examples of high impact and high quality publications co-authored by AstraZeneca and/or MedImmune scientists.


Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial

PUBLISHED
01 Oct 2016

TITLE
Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial

ASTRAZENECA/MEDIMMUNE AUTHOR
Marie Cullberg, Mohib K Uddin, Kai Richter, et al. 

Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function

PUBLISHED
12 May 2016

TITLE
Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function

ASTRAZENECA/MEDIMMUNE AUTHOR
Stephen I Rennard

Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation

PUBLISHED
September 2015

TITLE
Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation


ASTRAZENECA/MEDIMMUNE AUTHOR

Cohen S, Scott I, Majithiya J, Rapley L, Kemp B, England E, Rees G, Overed-Sayer C, Woods J, Bond N, Seguy-Veyssier C, Embrey K, Sims D, Snaith M, Vousden K, Strain M, Chan D, Carmen S, Huntington C, Flavell L, Xu J, Popovic B, Vaughan T, Butler R, Lowe D, Higazi D, Corkill D, May R, Sleeman M, Mustelin T

TH17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26

PUBLISHED
July 2015

TITLE
TH17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26

ASTRAZENECA/MEDIMMUNE AUTHOR
Yong-Jun Liu (MedImmune)

IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk

PUBLISHED
May 2015

TITLE
IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk

AstraZeneca/MedImunne AUTHOR
Richard May (MedImmune)

Our resources


Our focus on unmet medical needs

Improving patient outcomes with tailored therapies, devices, and support tools

  • Global burden of respiratory diseases

    Raising awareness of the ongoing unmet medical need in asthma, COPD and idiopathic pulmonary fibrosis (IPF)


  • Inhaled therapies and novel combinations

    Optimising our portfolio of inhaled medicines to improve choice and outcomes for patients across the disease spectrum


  • Targeted biologic therapies

    Using new scientific insights about the biology of respiratory diseases and patient phenotypes to create targeted biologic therapies




Partnering case studies